Madrigal Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Madrigal Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MDGL
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia.
CEOWilliam J. Sibold
CEOWilliam J. Sibold
Employees528
Employees528
HeadquartersWest Conshohocken, Pennsylvania
HeadquartersWest Conshohocken, Pennsylvania
Founded2000
Founded2000
Employees528
Employees528
MDGL Key Statistics
Market cap9.92B
Market cap9.92B
Price-Earnings ratio-32.10
Price-Earnings ratio-32.10
Dividend yield—
Dividend yield—
Average volume344.06K
Average volume344.06K
High today$469.95
High today$469.95
Low today$380.00
Low today$380.00
Open price$405.33
Open price$405.33
Volume1.25M
Volume1.25M
52 Week high$469.95
52 Week high$469.95
52 Week low$265.00
52 Week low$265.00
MDGL News
TipRanks 1h
Madrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor FitzgeraldCantor Fitzgerald upgraded Madrigal Pharmaceuticals (MDGL) to Overweight from Neutral. Published first on TheFly – the ultimate source for real-time, market-mo...
TipRanks 1d
Madrigal Pharmaceuticals upgraded to Neutral at BofA after Rezdiffra outperformsAs previously reported, BofA upgraded Madrigal Pharmaceuticals (MDGL) to Neutral from Underperform with a price target of $445, up from $266. MASH treatment Rez...
Analyst ratings
88%
of 17 ratingsBuy
88.2%
Hold
11.8%
Sell
0%
People also own
Based on the portfolios of people who own MDGL. This list is generated using Robinhood data, and it’s not a recommendation.